Johnson & Johnson is reported to trial its experimental Covid-19 vaccine with 6,000 UK volunteers on a two-dose basis in a phase 3 trial
If successful, the next step would be to approach regulators for approval.
This is good news for markets in anticipation of a return to normality when the vaccines are distributed to the populations.
it follows last week’s game-changer with the press release from Pfizer and BioNTech that said they had identified 94 cases of COVID-19 among 43,538 trial participants.
The threshold that the US Food and Drug Administration (FDA) says is required for a coronavirus vaccine to be approved for emergency use is just 50% and so far, the trial is proving a 90% success rate.
Meanwhile, there are still uncertainties as to the details about the nature of the infections the vaccine can protect against.
Market implications
Nevertheless, markets are pricing in a best-case scenario.
Share
